Why the study?
Does gastric bypass (RYGB) improve non-HDL cholesterol, LDL/HDL-ratio, and Lp(a) levels more than sleeve gastrectomy (SG) in adult patients with morbid obesity?
Population
Adult patients with morbid obesity
Comparison
Gastric bypass (RYGB) vs Sleeve gastrectomy (SG)
Design
Cohort
Follow-up
12 months
Key result
Roux-en-Y gastric bypass significantly reduced lipoprotein(a) by an additional 8.5 nmol/L and non-HDL cholesterol by 0.52 mmol/L compared to sleeve gastrectomy at 6 to 12 months postoperatively.
Authors
Loading...
May favor RYGB for lipid management in obesity; hypothesis-generating and requires randomized confirmation.
Cohort (n=111)
No
Does gastric bypass (RYGB) improve non-HDL cholesterol, LDL/HDL-ratio, and Lp(a) levels more than sleeve gastrectomy (SG) in adult patients with morbid obesity?
Mean Difference: -8.5 (95% CI -17–-0.04)
Absolute Event Rate: -13.8% vs -5.3%
p-value: p=0.049
Roux-en-Y gastric bypass is more effective than sleeve gastrectomy at improving dyslipidemia, including lowering Lp(a), in patients with morbid obesity.
Aaseth et al. (2022) conducted a cohort in Morbid obesity (n=111). Roux-en-Y gastric bypass (RYGB) vs. Sleeve gastrectomy (SG) was evaluated on Change in lipoprotein(a) levels (nmol/L) (MD -8.5, 95% CI -17.0 to -0.04, p=0.049). Roux-en-Y gastric bypass significantly reduced lipoprotein(a) by an additional 8.5 nmol/L and non-HDL cholesterol by 0.52 mmol/L compared to sleeve gastrectomy at 6 to 12 months postoperatively.